This past week has been a strange one for me, as it’s marked the 15th anniversary of hearing four awful words: “You have Parkinson’s disease ... going to end sooner rather than later ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...

Background: Gait disorder is a prominent motor symptom in Parkinson’s disease (PD), objective and quantitative assessment of gait is essential for diagnosing and treating PD, particularly in its early ...

An experimental immunotherapy candidate targets toxic species of alpha-synuclein and was well tolerated in an ongoing, ...

An experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's significantly reduce ...

Earlier this year, PRECEDENT Phase 2 study of dalzanemdor in people with mild cognitive impairment in Parkinson’s Disease also failed to meet its primary endpoint. The companies recently ...

Earlier this year, PRECEDENT Phase 2 study of dalzanemdor in people with mild cognitive impairment in Parkinson’s Disease also failed to meet its primary endpoint. In September, Sage Therapeutics ...

“Towards the end of my time (Queensland ... You do go through stages where you think “why me?’’ But a lot more people are getting it these days. Parkinson’s affects people in different ...

For most people, this wouldn’t be anything remarkable, but getting here was trickier for me than most — not because of the learning and upskilling required, but because I have end-stage kidney ...